格隆汇12月10日丨美好医疗(301363.SZ)在互动平台表示，脑机接口产品的成熟度和应用场景随着下游 客户产品的成熟和完善性能不断提高。公司正与下游脑机接口客户深入开展产品合作，协助客户实现从 实验室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

12月5日的资金流向数据方面，主力资金净流出933.9万元，占总成交额9.2%，游资资金净流入386.11万 元，占总成交额3.81%，散户资金净流入547.79万元，占总成交额5.4%。 证券之星消息，截至2025年12月5日收盘，美好医疗(301363)报收于21.42元，下跌0.46%，换手率 1.27%，成交量4.75万手，成交额1.01亿元。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：为全球医疗器械企业提供从产品设计开发到批量生产交付的 全流程一站式服务。 该股最近90天内共有13家机构给出评级，买入评级11家，增持评级2家；过去90天内机构目标均 ...

证券之星消息，截至2025年12月4日收盘，美好医疗(301363)报收于21.52元，上涨1.03%，换手率 1.68%，成交量6.27万手，成交额1.34亿元。 12月4日的资金流向数据方面，主力资金净流入531.81万元，占总成交额3.98%，游资资金净流出457.73 万元，占总成交额3.43%，散户资金净流出74.08万元，占总成交额0.55%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-04 | 21.52 | 1.03% | 531.81万 | 3.98% | -457.73万 | -3.43% | -74.08万 | -0.55% | | 2025-12-03 | | 21.30 0.42% | 2118.31万 | 13.39% | 1423.55万 | 9.00% | -3541.86万 | -22.38% | | 2025-12-02 | | 21.2 ...

近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-03 | 21.30 0.42% | | 2118.31万 | 13.39% | 1423.55万 | 9.00% | -3541.86万 | -22.38% | | 2025-12-02 | 21.21 0.09% | | -200.72万 | -3.54% | 260.69万 | 4.59% | -59.96万 | -1.06% | | 2025-12-01 | 21.19 | -0.19% | -232.84万 | -3.84% | -20.18万 | -0.33% | 253.02万 | 4.17% | | 2025-11-28 | 21.23 | 0.66% | -121.73万 | -1.81% | 164.01万 | 2.43% | -42.29万 | -0.63% | | 2025-11-27 | 21.09 | 0 ...

证券之星消息，截至2025年12月2日收盘，美好医疗(301363)报收于21.21元，上涨0.09%，换手率 0.72%，成交量2.7万手，成交额5676.04万元。 12月2日的资金流向数据方面，主力资金净流出200.72万元，占总成交额3.54%，游资资金净流入260.69 万元，占总成交额4.59%，散户资金净流出59.96万元，占总成交额1.06%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-02 | 21.21 0.09% | | -200.72万 | -3.54% | 260.69万 | 4.59% | -59.96万 | -1.06% | | 2025-12-01 | 21.19 -0.19% | | -232.84万 | -3.84% | -20.18万 | -0.33% | 253.02万 | 4.17% | | 2025-11-28 | 21.23 0 ...

Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]

最新公告列表 《2025年前三季度权益分派实施公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年11月28日收盘，美好医疗（301363）报收于21.23元，较前一交易日上涨0.66%，最新总市值 为120.77亿元。该股当日开盘21.09元，最高21.35元，最低21.01元，成交额达6742.93万元，换手率为 0.85%。 近日，美好医疗发布2025年前三季度权益分派实施公告。公告显示，公司2025年前三季度权益分派方案 已获通过，以总股本568,871,180股剔除回购股份1,132,048股后的567,739,132股为基数，向全体股东每10 股派发现金红利0.80元（含税），合计派发45,419,130.56元。本次不送红股，不进行资本公积转增股 本。股权登记日为2025年12月5日，除权除息日为2025年12月8日。现金红利由中国结算深圳分公司代 派，部分股东由公司自行派发。 ...

证券日报网讯 11月28日晚间，美好医疗发布公告称，本公司2025年前三季度权益分派方案为：以公司 现有总股本568，871，180股剔除回购专用证券账户中1，132，048股后的567，739，132股为基数，向 全体股东每10股派0.800000元人民币现金（含税）。股权登记日为2025年12月5日，除权除息日为2025 年12月8日。 （文章来源：证券日报） ...

1 证券代码：301363 证券简称：美好医疗 公告编号：2025-074 深圳市美好创亿医疗科技股份有限公司 2025年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、截至本公告披露日，深圳市美好创亿医疗科技股份有限公司（以下简称 "公司"或"本公司"）回购专用证券账户持有公司股份 1,132,048 股。根据《上 市公司股份回购规则》及《深圳证券交易所上市公司自律监管指引第 9 号——回 购股份》等相关规定，该部分已回购的股份不享有参与本次利润分配的权利。因 此，公司本次权益分派以现有总股本 568,871,180 股剔除回购专用证券账户持有 的 1,132,048 股后的 567,739,132 股为基数，向全体股东每 10 股派发现金红利人 民币 0.80 元（含税），合计派发现金红利人民币 45,419,130.56 元（含税）。本 次不送红股，不进行资本公积转增股本。 2、本次权益分派实施后，按公司总股本（含回购股份）折算的每 10 股现金 分红（含税）=本次实际现金分红总额÷公司总股本（含回购股份）×10 ...